// App-Quantinova.ai

Su1049 : Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-NaiVE Patients With Chronic Hepatitis C Genotype-1 Infection: a Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2)

Researchers

Presenter

  • Graham Foster

Principal Investigators

  • Peter Ferenci

  • Edward Tam

  • Kelly Kaita

  • S. Victor Feinman

  • Joseph Scherer

  • Stephen Olson

  • Anne-Marie Quinson

  • Curtis Cooper

  • Douglas T. Dieterich

  • Mark Sulkowski

  • Parvez S. Mantry

  • Robert Buynak

  • Tarek Hassanein

  • William M. Lee

  • David Wright

Medical Centers

  • Adelphi Communications, New York, NY

  • Queen Mary University of London, London, United Kingdom

  • School of Nursing, Johns Hopkins University, Baltimore, MD

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Mount Sinai Hospital, New York, NY

  • Central Texas Clinical Research, Austin, TX

  • The Liver Institute at Methodist Dallas Medical Center, Dallas, TX

  • University of Mantioba, Winnipeg, MB, Canada

  • Northwest Indiana Center for Clinical Research, Valparaiso, IN

  • Southern California Liver Centers, Coronado, CA

  • LAIR Centre, Vancouver, BC, Canada

  • Medical University of Vienna, Vienna, Austria

  • Hepatitis Center, Mount Sinai Hospital, New York, NY

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Health Studies, Pritzker School of Medicine, The University of Chicago, Chicago, IL

Locations

  • United States

  • Canada

  • United Kingdom

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis C

Biomarkers

  • Interleukin 28B

  • Interferon

  • Bilirubin

Drug/Treatment

  • interferon alfa-2a

  • Faldaprevir-sodium

  • Interferon

  • Ribavirin

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved